Humoral responses to multiple SARS-CoV-2 variants after two doses of vaccine in kidney transplant patients

Figures & data

Figure 1. The images of total antibodies and ACE2 bindings in HC and KT. The assay procedures involve the simultaneous quantification of total antibodies and surrogate neutralizing. The total antibodies in the serum were quantified using a Cy3-labelled anti-human IgG+IgA+IgM antibody. Concurrently, the surrogate neutralizing was quantified using Cy5-labelled ACE2.

Figure 2. Surrogate neutralizing against multiple spike ECDs in HC and KT after two doses of vaccines. HC and KT with 2 doses of vaccines were analysed for the surrogate neutralizing using the CoVariant arrays. Surrogate neutralizing against SARS-CoV-2 (a) wild-type ECD, (b) alpha ECD, (c) beta ECD, (d) gamma ECD, (e) delta ECD, and (f) omicron ECD. HC-AZ2 n = 15, KT-AZ2 n = 17, HC-M2 n = 15, KT-M2 n = 23. The data were analysed using one-way ANOVA, followed by Tukey’s post-hoc testing, with significance set at p < 0.05, denoted by distinct letters.

Figure 3. Profiling the serum antibody responses against multiple spike ECDs in HC and KT after two doses of vaccines. Vaccinated serums from HC and KT were used to quantify the total antibodies against various spike ECD by using the CoVariant arrays. Total antibodies against SARS-CoV-2 (a) wild-type ECD, (b) alpha ECD, (c) beta ECD, (d) gamma ECD, (e) delta ECD, and (f) omicron ECD. HC-AZ2 n = 15, KT-AZ2 n = 17, HC-M2 n = 15, KT-M2 n = 23. The data were analysed using one-way ANOVA, followed by Tukey’s post-hoc testing, with significance set at p < 0.05, denoted by distinct letters.

Data availability statement

The datasets generated in this study are available from the corresponding author upon reasonable request.